Tvardi Therapeutics, Inc. (TVRD) Form 10-Q — Aug 14, 2026
Tvardi Therapeutics reported a second-quarter 2026 net loss of $6.5 million, or $0.69 per share, on total operating expenses of $6.6 million, with the six-month net loss reaching $13.3 million. Cash and equivalents stood at $15.8 million at June 30, 2026, down from $20.7 million of cash plus $10.1 million of short-term investments at year-end, after $15.1 million of first-half operating cash burn. The company disclosed that substantial doubt exists about its ability to continue as a going concern, stating that present capital resources will not fund planned operations for at least one year.
Key figures
- Total Debt
- 0
- Total Assets
- 17517000
- Cash Position
- 15765000
- Shares Outstanding
- 13338943
- Ga expense q2 2026
- 2627000
- Q2 2025 net income
- 4167000
- Rd expense q2 2026
- 4002000
- Accumulated deficit
- 123711000
- Original atm capacity
- 12500000
- Uc us addressable market
- 3000000000
- New atm supplement capacity
- 9700000
- Shelf registration capacity
- 200000000
- Uc global addressable market
- 9000000000
- Shares outstanding aug 11 2026
- 13338943
- Shares outstanding jun 30 2026
- 9381344
- Atm gross proceeds post q2 2026
- 13300000
- Q2 2025 remeasurement gain convertible notes
- 12800000
Price after filing
Close on the filing date to close N calendar days later (from $1.90). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.